In:
Future Oncology, Future Medicine Ltd, Vol. 18, No. 7 ( 2022-03), p. 833-847
Abstract:
Plain language summary Cutaneous squamous cell carcinoma is a common skin cancer, with approximately 2 million cases diagnosed each year in the USA. Because substantial numbers of patients experience metastasis, which can result in death, accurate metastatic risk assessment is important. Clinicians use clinicopathologic factors to determine risk for disease progression. However, traditional methods miss pinpointing many patients who experience metastasis and sometimes categorize patients as at risk who do not develop metastasis, indicating that additional tools are needed. A molecular test, the 40-gene expression profile (40-GEP), was developed to predict metastatic risk based on the biology of the tumor. This study demonstrates that the 40-GEP, either as an independent tool or together with traditional methods, accurately identifies patients’ risk of metastasis. Using the 40-GEP could improve patient management to improve patient outcomes.
Type of Medium:
Online Resource
ISSN:
1479-6694
,
1744-8301
DOI:
10.2217/fon-2021-1277
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2022
Bookmarklink